The White House is reportedly pulling the nomination for Heidi Overton, M.D., Ph.D., to lead the FDA just hours before the Senate was scheduled to vote on her confirmation.
The move hardly comes as a surprise after Overton’s confirmation hearing before the Senate Health, Education, Labor and Pensions (HELP) Committee drew contention.
The news was first reported by Axios on Tuesday evening.
In September, the HELP committee questioned Overton in a hearing marked by tightrope-walking on issues like vaccines, abortions, flavored vapes and whether or not President Donald Trump is capable of being wrong.
Overton conceded multiple times during the hearing that vaccines approved by the FDA, as well as the “abortion pill” mifepristone, are safe and effective. But she stopped short of admitting that Trump has been wrong when dispensing medical information out of line with what scientific evidence shows.
Overton’s nomination faced mounting pushback and uncertainty from senators ahead of a planned HELP Committee vote on Nov. 18. Fierce reached out to Sen. Ed Markey, the veteran Democratic lawmaker from Massachusetts, ahead of the vote, and he told Fierce that he would “vote against her nomination, and I urge my colleagues to do the same.”
“The FDA needs a leader who will stand up for science and for our kids’ safety, not one who stood by while both were undermined,” he added.
Republican Sen. Bill Cassidy of Louisiana, who chairs the Senate health committee, and other Republicans had also raised questions about Overton's nomination.
As support for Overton looked thin, Republicans were discussing Sen. Roger Marshall, a Kansas Republican, as a potential replacement, Semafor reported today.
Robert Steinbrook, M.D., health research group director for Public Citizen, commented today urging the HELP committee to reject Overton’s nomination: “The FDA needs a strong commissioner who stands for science and the integrity of the agency,” Steinbrook said. “Overton is the wrong choice for FDA Commissioner and has done nothing to dispel the well-founded reasons to oppose her candidacy.”
Analysts from Citi shared that the White House’s decision to pull the nomination has a negative impact on biopharma, “extending uncertainty around permanent agency leadership.”
“We view the withdrawal as a modest sentiment negative, but not a material near-term change to the regulatory environment facing most drug and biologics sponsors,” the analysts said in the note.
The withdrawal of Overton's nomination leaves a gap at an FDA that has already faced significant upheaval. The White House only shifted its focus to Overton in August, after the agency had spent three months without a permanent leader.
Since former FDA commissioner Marty Makary, M.D., departed the agency in May, Kyle Diamantas, who hails from the agency’s food regulation division, has been at the helm in an interim capacity.